206 related articles for article (PubMed ID: 30981875)
1. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.
Luethi D; Hoener MC; Krähenbühl S; Liechti ME; Duthaler U
Biochem Pharmacol; 2019 Jun; 164():129-138. PubMed ID: 30981875
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes.
Klette KL; Anderson CJ; Poch GK; Nimrod AC; ElSohly MA
J Anal Toxicol; 2000 Oct; 24(7):550-6. PubMed ID: 11043658
[TBL] [Abstract][Full Text] [Related]
3. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan.
Wild MJ; McKillop D; Butters CJ
Xenobiotica; 1999 Aug; 29(8):847-57. PubMed ID: 10553725
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of lysergic acid diethylamide (LSD): an update.
Libânio Osório Marta RF
Drug Metab Rev; 2019 Aug; 51(3):378-387. PubMed ID: 31266388
[TBL] [Abstract][Full Text] [Related]
5. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
6. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids.
Marill J; Capron CC; Idres N; Chabot GG
Biochem Pharmacol; 2002 Mar; 63(5):933-43. PubMed ID: 11911845
[TBL] [Abstract][Full Text] [Related]
8. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
10. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors.
Egan CT; Herrick-Davis K; Miller K; Glennon RA; Teitler M
Psychopharmacology (Berl); 1998 Apr; 136(4):409-14. PubMed ID: 9600588
[TBL] [Abstract][Full Text] [Related]
11. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD.
He X; Luo X; Liu Z; Hu G; Cheng Z
Xenobiotica; 2011 Oct; 41(10):844-50. PubMed ID: 21679010
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry.
Cai J; Henion J
J Anal Toxicol; 1996; 20(1):27-37. PubMed ID: 8837948
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.
Trapnell CB; Jamis-Dow C; Klecker RW; Collins JM
Antimicrob Agents Chemother; 1997 May; 41(5):924-6. PubMed ID: 9145845
[TBL] [Abstract][Full Text] [Related]
14. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.
Dolder PC; Liechti ME; Rentsch KM
J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28548305
[TBL] [Abstract][Full Text] [Related]
16. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
18. Effects of inducers and/or inhibitors on metabolism of lysergic acid diethylamide in rat liver microsomes.
Inoue T; Niwaguchi T; Murata T
Xenobiotica; 1980 Dec; 10(12):913-20. PubMed ID: 7210704
[TBL] [Abstract][Full Text] [Related]
19. LC-mS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions.
Klette KL; Horn CK; Stout PR; Anderson CJ
J Anal Toxicol; 2002; 26(4):193-200. PubMed ID: 12054358
[TBL] [Abstract][Full Text] [Related]
20. Characterization of iso-LSD metabolism using human liver microsomes in comparison to LSD and its applicability as urinary biomarker for LSD consumption.
Ng XQ; Goh EML; Hamzah A; Yao YJ; Moy HY
J Anal Toxicol; 2024 Jun; 48(5):281-288. PubMed ID: 38613436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
